Finance

Lists
Q3 2026 earnings • released • EPS miss -119.27% • Revenue miss -16.77%
See results
IAM:NASDAQ
Iambic Therapeutics, Inc.
$13.19
-7.50%
(-1.07) 1D
Nov 20, 11:08:11 AM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for IAM...
Open
$14.00
High
$14.00
Low
$12.88
Mkt. cap
625.22M
Avg. vol.
635.48K
Volume
74.04K
52-wk high
$25.00
52-wk low
$9.60
EPS
-$1.99
Shares outstanding
6.81M
No. of employees
171
Open
$14.00
High
$14.00
Low
$12.88
Mkt. cap
625.22M
Avg. vol.
635.48K
Volume
74.04K
52-wk high
$25.00
52-wk low
$9.60
EPS
-$1.99
Shares outstanding
6.81M
No. of employees
171
News stories
From web sources and news partners
About Iambic Therapeutics, Inc.
CEO-
Employees171
Founded2019
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websiteiambic.ai
Analyst ratings
Based on 3 analysts giving stock ratings to IAM in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for IAM in the last 3 months.
Highest
Current $13.19
$35.00 (+165.35%)
Average
$28.50 (+116.07%)
Lowest
$22.00 (+66.79%)
Analyst
Recommendation
Action
Price target
Projected
Date
Geoff Meacham
Citi
Buy
Reiterated
$22.00
+66.8%
11/18/2026
Akash Tewari
Jefferies
Buy
Initiated
$35.00
+165.4%
11/09/2026
Alec Stranahan
Bank of America Securities
Buy
Initiated
-
-
11/09/2026
Last report
Nov 16, 2026
Fiscal period
Q3 2026
-$6.22 / -$2.84
-119.27%miss
Revenue / Est. (USD)
11.35M / 13.64M
-16.77%miss
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Mar 2026
Jun 2026
Revenue
1.96M
1.96M
6.38M
6.38M
Cost of goods sold
16.47M
16.47M
28.57M
28.57M
Cost of revenue
16.47M
16.47M
28.57M
28.57M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.33M
3.33M
4.56M
4.56M
Operating expense
3.33M
3.33M
4.56M
4.56M
Total operating expenses
19.80M
19.80M
33.13M
33.13M
Operating income
-17.84M
-17.84M
-26.76M
-26.76M
Other non operating income
-27.50K
-27.50K
-15.00K
-15.00K
EBT including unusual items
-16.58M
-16.58M
-25.06M
-25.06M
EBT excluding unusual items
-16.58M
-16.58M
-25.06M
-25.06M
Income tax expense
-
-
1.00K
1.00K
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-16.58M
-16.58M
-25.06M
-25.06M
Net profit margin
-844.32%
-844.32%
-392.97%
-392.97%
Earnings per share
-
-
-
-
Interest and investment income
1.29M
1.29M
1.72M
1.72M
Interest expense
-4.50K
-4.50K
-2.50K
-2.50K
Net interest expenses
1.28M
1.28M
1.71M
1.71M
Depreciation and amortization charges
-
-
-
-
EBITDA
-17.57M
-17.57M
-26.41M
-26.41M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps